Melina Gracia*
Cardiotoxicity induced by systemic therapy poses a significant concern in the management of breast cancer, particularly in women undergoing treatment. The ability to predict and mitigate the risk of cardiotoxicity is crucial for improving patient outcomes and quality of life. In recent years, there has been a growing interest in harnessing clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity. This review explores the emerging perspectives and advancements in utilizing clinical biomarkers to identify women with breast cancer who are at a higher risk of developing cardiotoxicity during systemic therapy. A comprehensive analysis of recent studies and clinical trials is presented, focusing on the evaluation and validation of various biomarkers, including but not limited to cardiac troponins, natriuretic peptides, imaging modalities, and genetic markers. The emerging perspectives on harnessing clinical biomarkers for predicting systemic therapy-induced cardiotoxicity in women with breast cancer hold significant promise in improving patient care and outcomes. Continued research, collaborative efforts, and innovative approaches are needed to refine and validate these biomarkers, ultimately facilitating their integration into routine clinical practice and enabling personalized management strategies for this vulnerable patient population.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 